Revelation Biosciences (REVB) Net Cash Flow (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Net Cash Flow of -$2.0 million for Q4 2025, down 4677.46% year-over-year from $43870.6 in Q4 2024, and down 126.65% quarter-over-quarter from $7.5 million in Q3 2025.
Revelation Biosciences (REVB) Net Cash Flow (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Net Cash Flow for 6 consecutive years, with -$2.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow fell 4677.46% year-over-year to -$2.0 million; the TTM figure through Dec 2025 stood at $812772.0 (up 114.8% YoY), while the FY2025 annual figure was $4.2 million, up 176.49% from the prior year.
- Net Cash Flow slipped to -$2.0 million in Q4 2025 per REVB's latest filing, from $7.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $12.4 million in Q1 2023 and bottomed at -$5.5 million in Q3 2024.
- Historically, Net Cash Flow has averaged $140969.5 across 5 years, with a median of -$2.0 million in 2023.
- On a YoY basis, Net Cash Flow climbed as much as 236.2% in 2025 and fell as far as 4677.46% in 2025.
- Revelation Biosciences' Net Cash Flow stood at -$2.9 million in 2021, then surged by 67.08% to -$942467.0 in 2022, then tumbled by 112.51% to -$2.0 million in 2023, then soared by 97.9% to -$42034.0 in 2024, then plunged by 4677.46% to -$2.0 million in 2025.
- Business Quant data shows REVB's Net Cash Flow at -$2.0 million in Q4 2025, $7.5 million in Q3 2025, and -$1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 225.59 Mn |
| 10 | Revelation Biosciences | 4.13 Mn | -7.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.01 Mn |
| Dec 31, 2025 | -2.01 Mn |
| Sep 30, 2025 | 7.53 Mn |
| Sep 30, 2025 | 7.53 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Dec 31, 2024 | -42,034.00 |
| Dec 31, 2024 | -42,034.00 |
| Sep 30, 2024 | -5.53 Mn |
| Sep 30, 2024 | -5.53 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.56 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Sep 30, 2023 | -1.72 Mn |